IBA Secures Fourth Proteus®ONE Proton Therapy Deal in Taiwan

Event summary

  • IBA signs contract for a Proteus®ONE proton therapy system at MacKay Memorial Hospital in New Taipei City, Taiwan.
  • This is the fourth Proteus®ONE system ordered in Taiwan, reinforcing IBA’s market leadership.
  • The system, featuring DynamicARC® beam delivery capabilities, is expected to start treating patients in 2029.
  • The contract includes delivery, installation, and a comprehensive Quality Assurance package from IBA Dosimetry.

The big picture

IBA’s latest contract in Taiwan underscores its strategic focus on expanding proton therapy solutions in high-growth Asian markets. The deal further solidifies its position as the global leader in proton therapy, with the Proteus®ONE system serving as a key differentiator. The typical end-user price for such systems ranges between EUR 35 and 45 million, highlighting the significant investment in advanced cancer treatment infrastructure.

What we're watching

Market Penetration
Whether IBA can sustain its dominance in the Asian proton therapy market with additional contracts.
Regulatory Clearance
The pace at which DynamicARC® beam delivery capabilities receive regulatory approval.
Execution Risk
How IBA manages the installation and integration of the system to meet the 2029 patient treatment start date.